In Vivo Validation of Glutamate-Aspartate Antiporter EAAT1 as a Therapeutic Target for T-Cell Acute Lymphoblastic Leukaemia

Project Details

Short titleIn Vivo Validation of Glutamate-Aspartate Antiporter EAAT1 as a Therapeutic Target for T-Cell Acute Lymphoblastic Leukaemia
StatusFinished
Effective start/end date1/01/2031/12/20

Funding

  • Cancer Research Uk